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Adults more than 40 years old are not necessarily immune to measles. 
A measles outbreak that involved healthcare workers occurred after 
contact with a 44-year-old patient. Results of a hospitalwide program 
of mass screening revealed that 117 (4.5%) of 2,600 individuals tested 
seronegative for measles; 31 (26.1%) of these 117 individuals were 
more than 40 years old. 
Infect Control Hosp Epidemiol 2007; 28:1117-1120 
Measles is a highly contagious disease and one of the most 
frequent causes of vaccine-preventable infant mortality world-
wide. The disease is usually more severe in adults and in 
immunocompromised patients.1 Because a single dose of vac-
cine confers only 90% protection, a second dose is recom-
mended to reduce the rate of primary vaccine failure. In 
Switzerland, vaccination against measles has been recom-
mended for the general public since 1976 by public health 
authorities but is not mandatory. Adults born before the mid-
1960s are believed to be immune, because so many children 
in that era were exposed to the measles virus and thus de-
veloped natural and permanent protection.2 Hence, in most 
developed countries, individuals more than 40 years old are 
considered to have lifelong immunity. 
In January 2005, 4 healthcare workers (HCWs) at the Uni-
versity of Geneva Hospitals were involved in a nosocomial 
outbreak of measles, together with 35 other individuals iden-
tified in the community. The index patient was a 44-year-old 
man admitted with cough, fever, and macular rash who stayed 
16 hours overnight without isolation precautions in a single 
bay in the emergency department before receiving a diagnosis 
of measles infection. Two other adults in his workplace be-
came infected, as did the children of a 43-year-old nurse. 
None had a past history of receiving 2 doses of vaccine in 
accordance with national recommendations,2 but at least 3 
of the adults recalled a past infection during childhood. No 
severe complications occurred, with the exception of 1 case 
of secondary bacterial pneumonia. Given the incomplete 
knowledge of the immunity status of the hospital's HCWs 
and to contain the possibility of a large nosocomial epidemic, 
a hospitalwide campaign of mass screening and vaccination 
against measles was initiated in February 2005. 
M E T H O D S 
A comprehensive plan for employee screening and vaccina-
tion was rapidly designed. HCWs with patient contact were 
included on a mandatory basis regardless of age and were 
given the choice of being vaccinated directly or being tested 
for measles-specific immunoglobulin G (IgG) antibodies to 
test their immunity. Employees without patient contact were 
considered less likely to be at risk for nosocomial measles, 
and their participation was voluntary. Medical history or past 
medical reports of measles were not accepted as proof of 
immunity. Only HCWs with written confirmation of the re-
ceipt of 2 doses of vaccine or with a prior positive result of 
serologic testing were considered protected. Seronegative, 
nonpregnant HCWs were vaccinated with 1 dose of an at-
tenuated trivalent mumps, measles, and rubella (MMR) vac-
cine. A second dose of vaccine was given within the following 
3 months. Immunocompromised patients with long periods 
of hospitalization and families of transplant recipients who 
were followed up at our hospital were included in the screen-
ing on a voluntary basis. 
The presence of IgG antibodies against measles was assessed 
by an indirect enzyme-linked immunosorbent assay (Enzyg-
nost Anti-Measles Virus/IgG; Dade Behring Diagnostics) in 
accordance with the manufacturer's instructions. Testing of 
cellular immunity was not performed. 
RESULTS 
A total of 3,233 HCWs with direct contact with patients, 
approximately 150 transplant recipients, and approximately 
250 family members of transplant recipients were included 
in the campaign. A third (1,100 of 3,233) of the HCWs pre-
ferred to directly receive the MMR vaccine (Figure). Within 
6 months, approximately 2,600 adults at our hospital (in-
cluding approximately 2,300 HCWs) were tested for the pres-
ence of IgG antibodies. Of those tested, 117 (4.5%) were 
found to be seronegative, and 31 (26%) of those 117 were 
more than 40 years old. Of those 31, 14 were HCWs in good 
health, and 1 had a smoldering myeloma. The oldest HCW 
was a 76-year-old female volunteer. Of the 17 seronegative 
patients more than 40 years old, 8 were immunocompetent 
and 9 were immunocompromised: 2 bone marrow transplant 
recipients, 4 renal transplant recipients, 1 cardiac transplant 
recipient, 1 with cirrhosis, and 1 with acquired immunode-
ficiency syndrome. 
D I S C U S S I O N 
Overall, 4.5% of all individuals tested by serological analysis 
at our hospital were shown to be susceptible to measles. Of 
these, 26% were born before the introduction of the MMR 
vaccine. However, one-third of all HCWs opted to be directly 
vaccinated rather than undergo serologic testing, probably 
because they considered themselves likely to be nonimmune; 
thus, the overall prevalence of seronegativity might have been 
underestimated. During outbreaks of measles, serologic screen-
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FIGURE. Flowchart of healthcare workers (HCWs) and patients who participated in the mass screening and vaccination campaign against 
nosocomial measles at the University of Geneva Hospitals, February-July 2005. 
ing before vaccination is not recommended, because rapid 
vaccination is more important to halt the transmission of 
disease.3 
Importantly, and contrary to common belief and Swiss 
national recommendations,2 the age limit does not replace 
serologic immunity testing for measles. Recommendations for 
adults who do not work in health care vary among countries. 
In Canada, England, and Wales, individuals more than 35 
years old are considered less likely to be susceptible to measles, 
whereas in France and Germany, vaccination against measles 
is not recommended for adults more than 25 and 18 years 
old, respectively. Conversely, in Austria, there is no age limit 
for measles vaccination, and the US Centers for Disease Con-
trol and Prevention recommendations favor 1 vaccine dose 
for adults more than 50 years old.3 Nevertheless, measles cases 
among very old individuals are rare, and it is probable that 
TABLE. Healthcare Workers (HCWs) Who Tested Seronegative for Measles, 1992-2006 
Study Place 
No. of 
HCWs 
Seronegative 
HCWs, % 
Age limit for 
testing, years 
Nonimmune 
HCWs, %a 
Celikbas et al.,9 2006 
Hatakeyama et al.,10 2004 
Ammari et al.,11 1993 
Ferson,12 1994 
Fedeli et al.,13 2002 
Ziegler et al.,14 2003 
Willy et al.,15 1994 
Steingart et al.,1 1999 
Kim et al.,16 1992 
Asari et al.,17 2003 
Seo et al.,18 2002 
Wright and Carlquist,19 1994 
Almuneef et al.,20 2006 
Ankara, Turkey 
Tokyo, Japan 
Philadelphia, PA 
Sydney, Australia 
Padua, Italy 
Cambridge, United Kingdom 
Bethesda, MD 
United States (various 
Hawaii 
Osaka, Japan 
New York City, NY 
Utah 
Riyadh, Saudi Arabia 
hospitals) 
363 
877 
900 
235 
333 
218 
2,473 
7,535 
2,075 
271 
1,349 
5,825 
4,006 
1.4 
1.5 
1.5 
1.7 
1.8 
3.3 
4.0 
4.0 
4.9 
7.4 
9.0 
10.3 
13.0 
None 
32 
None 
None 
45 
None 
38 
None 
40 
31 
39 
35 
None 
NR 
0 
NR 
NR 
0 
NR 
8.6 
NR 
7.9 
12.5 
3.1 
8.1 
NR 
N O T E . NR, not reported. 
" Above age limit for testing. 
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the upper age limit for the risk of measles is not indefinitely 
high. On the basis of our experience during the nosocomial 
outbreak described here that involved at least 2 immuno-
competent adults more than 40 years old, we believe that the 
risk is real for this age group, among both patients and HCWs. 
It is known that transplant recipients can lose seropositivity 
for measles after undergoing transplantation,4 antibodies can 
wane over time even in healthy individuals,5 and exposure to 
wild-type virus is less common today, which potentially re-
sults in an inferior boosting of immunity, similar to what has 
been discussed for varicella zoster virus in a highly vaccinated 
population. The small number of seronegative transplant re-
cipients does not alter the key message of our report. Im-
munity to measles is conferred by the interplay of humoral 
and cellular responses. Serum antibodies may only partly cor-
relate with protection against measles infection or disease, 
but the relative contribution of cellular immunity to protec-
tion in response to vaccination remains unknown.6 In ac-
cordance with common practice and recommendations,3 we 
did not measure cellular immunity in our campaign. 
In Switzerland, despite reimbursement by health insurance, 
general vaccination coverage is insufficient, mostly because 
of alternative beliefs, particularly among nurses.7 Coverage 
against measles falls short of the amount needed to prevent 
the regular occurrence of outbreaks, which requires a herd 
immunity of more than 95%.8 Internationally, the prevalence 
of susceptibility to measles among HCWs ranges from 1.4% 
to 13% (Table), and only a few reports provide details of the 
age groups involved among nonimmune HCWs. Our results 
are in agreement with those from other countries. The vac-
cination status of HCWs is considered a parameter for patient 
safety in healthcare institutions.21 HCWs have a nearly 19-
fold higher risk of infection with measles compared with that 
of the general population.1 Of note, 27% of all measles cases 
in the United States during 1993-1995 involved individuals 
more than 20 years old, with 13.9% occurring in a healthcare 
setting.1 
A hospital is responsible for the health of its employees 
and patients. Given the high contagiousness of the measles 
virus, the severity of the disease in adults, and the safety and 
cost-effectiveness of the vaccine, all medical institutions 
should ensure that all HCWs are immunized against measles.3 
Importantly, age should no longer be considered in the de-
cision of whether to vaccinate.3,22 Instead, proof of immunity 
by direct vaccination or serological analysis should be man-
datory, as is now the case for every new employee at our 
hospital. However, compliance with these recommendations 
is poor1 and clearly must be reinforced in hospitals and in 
the general population. 
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